As there are economic modelling papers in the pipeline to be...

As there are economic modelling papers in the pipeline to be published,
the odds on there being 'no data' are kinda low to negligible

As I have seen at least some data that could be used to write such paper (see older ASX announcements) it is just not so.

While I dont know the costs of various alternatives, the outcome of healing at least some of the wounds in patients whose clinical history suggested they would never heal (had had the ulcer for long long time) suggests strong economic rationale for vitrogro and while that is a wet finger estimate. Personal experience with my past wet finger estimates,suggest to me it will be the result of any thorough analysis
I expect the analysis will have to do interesting things to establish the expected baseline costs, of patients without vitrogro as we have not yet done the full clinical trial kind of work that the US wants. However retrospectively finding say matched pairs based on clinical histories, would be a sensible approach to using the data they do have, and have published. (see the old case studies, that were the basis of the healing graph in the AGM slides)